作者
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry JM Groen, Daniel SW Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov, Egbert F Smit, Pierre-Jean Souquet, Johan Vansteenkiste, Maximilian Hochmair, Enriqueta Felip, Makoto Nishio, Michael Thomas, Kadoaki Ohashi, Ryo Toyozawa, Tobias R Overbeck, Filippo de Marinis, Tae-Min Kim, Eckart Laack, Anna Robeva, Sylvie Le Mouhaer, Maeve Waldron-Lynch, Banu Sankaran, O Alejandro Balbin, Xiaoming Cui, Monica Giovannini, Mikhail Akimov, Rebecca S Heist
发表日期
2020/9/3
期刊
New England Journal of Medicine
卷号
383
期号
10
页码范围
944-957
出版商
Massachusetts Medical Society
简介
Background
Among patients with non–small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models with various types of MET activation.
Methods
We conducted a multiple-cohort, phase 2 study evaluating capmatinib in patients with MET-dysregulated advanced NSCLC. Patients were assigned to cohorts on the basis of previous lines of therapy and MET status (MET exon 14 skipping mutation or MET amplification according to gene copy number in tumor tissue). Patients received capmatinib (400-mg tablet) twice daily. The primary end point was overall response (complete or partial response), and the key secondary end point was response duration; both end points were assessed by an independent review committee whose members were unaware of the …
学术搜索中的文章
J Wolf, T Seto, JY Han, N Reguart, EB Garon… - New England Journal of Medicine, 2020
G Mono, J Wolf, T Seto, JY Han, N Reguart, EB Garon… - New England Journal of Medicine, 2020
